1. A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience. (25th March 2021) Authors: Pauli, Chantal; Bochtler, Tilmann; Mileshkin, Linda; Baciarello, Giulia; Losa, Ferran; Ross, Jeffrey S.; Pentheroudakis, George; Zarkavelis, George; Yalcin, Suayib; Özgüroğlu, Mustafa; Beringer, Andreas; Scarato, Jeremy; Mueller‐Ohldach, Mathis; Thomas, Marlene; Moch, Holger; Krämer, Alwin Journal: Oncologist Issue: Volume 26:Number 5(2021) Page Start: e769 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Azacitidine and low‐dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts – a retrospective single‐center experience. (3rd April 2014) Authors: Radujkovic, Aleksandar; Dietrich, Sascha; Bochtler, Tilmann; Krämer, Alwin; Schöning, Tilman; Ho, Anthony D.; Dreger, Peter; Luft, Thomas Journal: European journal of haematology Issue: Volume 93:Number 2(2014:Aug.) Page Start: 112 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome. Issue 11 (29th April 2019) Authors: Bochtler, Tilmann; Endris, Volker; Leichsenring, Jonas; Reiling, Anna; Neumann, Olaf; Volckmar, Anna‐Lena; Kirchner, Martina; Allgäuer, Michael; Schirmacher, Peter; Krämer, Alwin; Stenzinger, Albrecht Journal: International journal of cancer Issue: Volume 145:Issue 11(2019) Page Start: 2963 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. (March 2014) Authors: Bochtler, Tilmann; Hegenbart, Ute; Kunz, Christina; Benner, Axel; Seckinger, Anja; Dietrich, Sascha; Granzow, Martin; Neben, Kai; Goldschmidt, Hartmut; Ho, Anthony D.; Hose, Dirk; Jauch, Anna; Schönland, Stefan O. Journal: Amyloid Issue: Volume 21:Number 1(2014:Mar.) Page Start: 9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. Issue 11 (11th March 2020) Authors: Bochtler, Tilmann; Reiling, Anna; Endris, Volker; Hielscher, Thomas; Volckmar, Anna‐Lena; Neumann, Olaf; Kirchner, Martina; Budczies, Jan; Heukamp, Lukas C.; Leichsenring, Jonas; Allgäuer, Michael; Kazdal, Daniel; Löffler, Harald; Weichert, Wilko; Schirmacher, Peter; Stenzinger, Albrecht; Krämer,... Journal: International journal of cancer Issue: Volume 146:Issue 11(2020) Page Start: 3053 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary. (November 2021) Authors: Pouyiourou, Maria; Wohlfromm, Timothy; Kraft, Bianca; Hielscher, Thomas; Stichel, Damian; von Deimling, Andreas; Delorme, Stefan; Endris, Volker; Neumann, Olaf; Stenzinger, Albrecht; Krämer, Alwin; Bochtler, Tilmann Journal: European journal of cancer Issue: Volume 157(2021) Page Start: 179 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Issue 12 (December 2018) Authors: Platzbecker, Uwe; Middeke, Jan Moritz; Sockel, Katja; Herbst, Regina; Wolf, Dominik; Baldus, Claudia D; Oelschlägel, Uta; Mütherig, Anke; Fransecky, Lars; Noppeney, Richard; Bug, Gesine; Götze, Katharina S; Krämer, Alwin; Bochtler, Tilmann; Stelljes, Matthias; Groth, Christoph; Schubert, Antje; M... Journal: Lancet oncology Issue: Volume 19:Issue 12(2018) Page Start: 1668 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Mesenchymal stromal cells contribute to quiescence of therapy‐resistant leukemic cells in acute myeloid leukemia. (13th September 2017) Authors: Wang, Wenwen; Bochtler, Tilmann; Wuchter, Patrick; Manta, Linda; He, Haiju; Eckstein, Volker; Ho, Anthony D.; Lutz, Christoph Journal: European journal of haematology Issue: Volume 99:Number 5(2017) Page Start: 392 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Micronucleus formation in human cancer cells is biased by chromosome size. Issue 6 (17th January 2019) Authors: Bochtler, Tilmann; Kartal‐Kaess, Mutlu; Granzow, Martin; Hielscher, Thomas; Cosenza, Marco R.; Herold‐Mende, Christel; Jauch, Anna; Krämer, Alwin Journal: Genes, chromosomes & cancer Issue: Volume 58:Issue 6(2019) Page Start: 392 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Phase I dose‐escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia. (8th June 2018) Authors: Ottmann, Oliver G.; Müller‐Tidow, Carsten; Krämer, Alwin; Schlenk, Richard F.; Lübbert, Michael; Bug, Gesine; Krug, Utz; Bochtler, Tilmann; Voss, Florian; Taube, Tillmann; Liu, Dan; Garin‐Chesa, Pilar; Döhner, Hartmut Journal: British journal of haematology Issue: Volume 184:Number 6(2019) Page Start: 1018 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗